Serum triglycerides and risk of cardiovascular disease

被引：121

作者：

Boullart, A. C. I. ^{[1
]}

de Graaf, J. ^{[1
]}

Stalenhoef, A. F. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Div Vasc Med, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2012年 / 1821卷 / 05期

关键词：

Triglyceride; Hypertriglyceridemia; Metabolism; Lipid lowering drug; Cardiovascular disease; CORONARY-HEART-DISEASE; GENETICALLY HYPERLIPIDEMIC RABBITS; LOW-DENSITY LIPOPROTEINS; METABOLIC SYNDROME; NONFASTING TRIGLYCERIDES; ENDOTHELIAL FUNCTION; PLASMA-LIPOPROTEIN; MYOCARDIAL-INFARCTION; CHOLESTERYL ESTER; LDL CHOLESTEROL;

D O I：

10.1016/j.bbalip.2011.10.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Dyslipidemia, especially elevated serum levels of cholesterol, is causally related to cardiovascular disease. The specific role of triglycerides has long been controversial. In this article we discuss the role of serum triglycerides in relation to the risk of cardiovascular disease. First, the (patho)physiology of triglycerides is described, including the definition and a short summary of the primary and secondary causes of hypertriglyceridemia. Furthermore, we will give an overview of the published epidemiological studies concerning hypertriglyceridemia and cardiovascular disease to support the view that triglyceride-rich lipoproteins are an independently associated risk factor. Finally, treatment strategies and treatment targets are discussed. This article is part of a Special Issue entitled Triglyceride Metabolism and Disease. (C) 2011 Elsevier B.V. All rights reserved.

引用

页码：867 / 875

页数：9

共 117 条

[1]

Assmann G, 1998, EUR HEART J, V19, pA2

[2] ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].